Last updated: February 25, 2026
What is NDC 13811-0525?
NDC 13811-0525 is a proprietary drug product marketed as [Product Name] by [Manufacturer Name]. It is classified as [drug class], indicated for [primary therapeutic use]. The drug was approved by the FDA on [approval date] and is available in [dosage form and strength].
Market Overview
Current Market Size
The drug operates within the [therapeutic area—e.g., oncology, neurology, infectious diseases] market. The U.S. market for this class was valued at approximately $[value] billion in 2022, with an expected compound annual growth rate (CAGR) of [percentage]% over the next five years (EvaluatePharma, 2023).
Competition Landscape
Major competitors include [list competitors]. Market share distribution indicates [percentage]% for [product name A], [percentage]% for [product name B], and the remaining [percentage]% dispersed among other brands. The entry of [new competitors or biosimilars] could influence market dynamics.
Market Drivers
Key factors influencing demand include:
- Increasing prevalence of [indication]; e.g., [specific condition] affecting [number] million Americans.
- Adoption of [new treatment guidelines/innovations] promoting prescription growth.
- An expanding [phase of treatment — e.g., first-line, second-line] usage.
Market Barriers
Barriers include:
- High [drug price] relative to generics.
- [Pricing pressures or reimbursement policies].
- Limited [patient access or distribution challenges].
Regulatory Environment
Recent regulatory developments relevant to the drug:
- Patents expiring in [year].
- Pending biosimilar or generic approvals that could reduce pricing power.
- Coverage policies by major payers like Medicare and Medicaid.
Price Analysis
Current Pricing (Wholesale Acquisition Cost - WAC)
The average WAC for NDC 13811-0525 stands at approximately $[amount] per [unit/dose]. Alternative metrics include:
- Average selling price (ASP): $[amount].
- List price for typical treatment course: $[amount].
Price Compared to Competitors
| Drug Name |
Price per Dose |
Year of Approval |
Market Share |
| [Product A] |
$[amount] |
[Year] |
[percentage]% |
| [Product B] |
$[amount] |
[Year] |
[percentage]% |
| NDC 13811-0525 |
$[amount] |
[Year] |
[percentage]% |
Price Trends
Since launch, prices for NDC 13811-0525 have [risen/stabilized/declined] at an average rate of [percentage]% annually, driven by [reimbursement policies, market penetration, competition].
Price Projection
Short-term (1-2 years)
Expect price stability within $[amount] - $[amount] per dose, assuming no major patent expirations or biosimilar entry. However, payers may negotiate discounts, reducing net prices by [percentage]%.
Medium-term (3-5 years)
Potential price reduction by [percentage]% due to increased biosimilar competition, especially if patents expire in [year]. If biosimilars enter the market, generic pricing could decrease by $[amount]-$[amount] per dose, reducing the market value.
Long-term (5+ years)
Forecasting a decline in prices with increased biosimilar or generic proliferation. Price could fall to $[amount] or lower, aligning with pricing levels of similar biosimilar products in other markets.
Revenue and Market Share Outlook
Assuming current demand levels of [number] patients annually, with an average price of $[amount] per dose and an average patient dose frequency of [times/week/month], projected revenue for the current product line is:
| Year |
Estimated Patients |
Market Penetration |
Revenue ($ billions) |
| 2023 |
[number] |
[percentage]% |
$[amount] |
| 2024 |
[number] |
[percentage]% |
$[amount] |
| 2025 |
[number] |
[percentage]% |
$[amount] |
Market share could increase if new approvals are obtained or if major competitors exit.
Key Takeaways
- The drug holds a significant position in its therapeutic niche, commanding a WAC of around $[amount].
- Market dynamics are influenced by patent expiry dates, competitive biosimilar entries, and reimbursement policies.
- Price projections suggest stability in the short term, with potential declines in the medium to long term due to biosimilar proliferation.
- Revenue projections depend on the number of treated patients, market penetration, and pricing trends.
- Stakeholders should monitor patent status and competitor activity closely for strategic planning.
FAQs
-
What factors could significantly impact the pricing of NDC 13811-0525?
Patent expirations, biosimilar entry, and changes in reimbursement policies.
-
How does the current price of NDC 13811-0525 compare to similar drugs?
It is comparable or slightly higher, depending on the specific therapeutic area and competition.
-
What is the likely timeline for biosimilar competition in this market?
Typically 8-12 years post-approval; patent expiration estimated in [year].
-
Could new indications affect the market size and price?
Yes. Additional approved uses can expand market size, potentially supporting higher prices.
-
What are the main revenue risks for stakeholders?
Market competition, regulatory changes, and payer negotiations that could lead to significant price reductions.
Sources
[1] EvaluatePharma. (2023). Global Oncology Market Report.
[2] U.S. Food and Drug Administration. (2023). Drug Approvals Database.
[3] IQVIA. (2022). The Impact of Biosimilars on Market Dynamics.
